Barinthus Biotherapeutics (BRNS) Depreciation & Amortization (CF) (2020 - 2026)

Barinthus Biotherapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $856000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 57.92% year-over-year to $856000.0; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 27.12% YoY), and the FY2025 full-year result was $5.8 million, up 0.78% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $856000.0, down from $909000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.0 million in Q1 2025, with the low at $856000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $1.3 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 1297.65% — and 2026, when it sank 57.92%.
• Barinthus Biotherapeutics' Depreciation & Amortization (CF) stood at $1.2 million in 2022, then advanced by 21.92% to $1.4 million in 2023, then dropped by 0.49% to $1.4 million in 2024, then slumped by 36.34% to $909000.0 in 2025, then retreated by 5.83% to $856000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $856000.0 (Q1 2026), $909000.0 (Q4 2025), and $901000.0 (Q3 2025), per Business Quant data.